Literature DB >> 2957924

Coxsackievirus B-3 myocarditis. Acute and chronic forms of the disease caused by different immunopathogenic mechanisms.

P A Lodge, M Herzum, J Olszewski, S A Huber.   

Abstract

Male BALB/c, DBA/2 and A mice inoculated with a myocarditic variant of coxsackievirus group B, Type 3 (CVB3) developed three distinct patterns of myocarditis. Most BALB/c and all DBA/2 mice developed acute cardiac inflammation lasting only 2 weeks, while A animals consistently showed twice as much myocardial damage as the other two strains, with active myocarditis continuing for 56 days after virus inoculation. Although virus elimination from the heart was also delayed in A mice, immunopathogenic, not viral, mechanisms caused cardiac injury in all strains. In vivo depletion of L3T4+ (T helper) and Lyt 2+ (T cytolytic/suppressor) cells using monoclonal antibodies showed that myocarditis in BALB/c mice depended predominantly on Lyt 2+ cells, in DBA/2 mice on L3T4+ cells and in A mice on both Lyt 2+ and L3T4+ cells. IgM heart reactive antibodies (HRAs) occurred in all three strains, while IgG HRAs were detected only in DBA/2 and A mice. Presumably, only the IgG antibody was pathogenic in this system. These data suggest that the host's genetic makeup determines the type of immune response to CVB3 infection of the heart and therefore the pattern of myocarditis which develops.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2957924      PMCID: PMC1899672     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  20 in total

1.  Lack of correlation between neutralizing antibody production and suppression of coxsackievirus B-3 replication in target organs: evidence for involvement of mononuclear inflammatory cells in host defense.

Authors:  J F Woodruff
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

2.  Generation of cytotoxic T lymphocytes during coxsackievirus B-3 infection. I. Model and viral specificity1.

Authors:  C Y Wong; J J Woodruff; J F Woodruff
Journal:  J Immunol       Date:  1977-04       Impact factor: 5.422

3.  A rapid solid-phase enzyme-linked binding assay for screening monoclonal antibodies to cell surface antigens.

Authors:  S P Cobbold; H Waldmann
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

4.  Genetic control of macrophage activation for killing of extracellular targets.

Authors:  E Skamene; S L James; M S Meltzer; M N Nesbitt
Journal:  J Leukoc Biol       Date:  1984-01       Impact factor: 4.962

5.  Coxsackievirus B3-induced myocarditis. Autoimmunity is L3T4+ T helper cell and IL-2 independent in BALB/c mice.

Authors:  M Estrin; S A Huber
Journal:  Am J Pathol       Date:  1987-05       Impact factor: 4.307

6.  Encephalomyocarditis virus myocarditis in inbred strains of mice--chronic stage.

Authors:  A Matsumori; C Kawai; S Sawada
Journal:  Jpn Circ J       Date:  1982-11

7.  Coxsackie virus B3 perimyocarditis in BALB/c mice: experimental model of chronic perimyocarditis in the right ventricle.

Authors:  A Matsumori; C Kawai
Journal:  J Pathol       Date:  1980-06       Impact factor: 7.996

8.  Cardiac injury in myocarditis induced by Coxsackievirus group B, type 3 in Balb/c mice is mediated by Lyt 2 + cytolytic lymphocytes.

Authors:  M Guthrie; P A Lodge; S A Huber
Journal:  Cell Immunol       Date:  1984-10-15       Impact factor: 4.868

9.  Characterization and myocarditic capabilities of coxsackievirus B3 variants in selected mouse strains.

Authors:  C J Gauntt; P T Gomez; P S Duffey; J A Grant; D W Trent; S M Witherspoon; R E Paque
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

10.  Coxsackievirus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens.

Authors:  S A Huber; P A Lodge
Journal:  Am J Pathol       Date:  1984-07       Impact factor: 4.307

View more
  35 in total

1.  Complement component 3 interactions with coxsackievirus B3 capsid proteins: innate immunity and the rapid formation of splenic antiviral germinal centers.

Authors:  D R Anderson; C M Carthy; J E Wilson; D Yang; D V Devine; B M McManus
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Immunomodulation of encephalomyocarditis virus-induced disease in A/J mice.

Authors:  M T Barger; J E Craighead
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

Review 3.  Innate and adaptive immune responses against picornaviruses and their counteractions: An overview.

Authors:  Andreas Dotzauer; Leena Kraemer
Journal:  World J Virol       Date:  2012-06-12

Review 4.  Role of cytotoxic T cells in experimental myocarditis.

Authors:  N Van Houten; S A Huber
Journal:  Springer Semin Immunopathol       Date:  1989

Review 5.  Anti-viral and anti-myocyte antibodies in experimental myocarditis.

Authors:  M Herzum; B Maisch
Journal:  Springer Semin Immunopathol       Date:  1989

Review 6.  Cardiac Autoimmunity: Myocarditis.

Authors:  William Bracamonte-Baran; Daniela Čiháková
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

7.  Reduced myocarditis following Coxsackievirus infection in cellular FLICE inhibitory protein--long form-transgenic mice.

Authors:  Sally Huber; Austin Dohrman; Danielle Sartini; Ralph C Budd
Journal:  Immunology       Date:  2006-09-28       Impact factor: 7.397

8.  Treatment of encephalomyocarditis virus-induced central nervous system demyelination with monoclonal anti-T-cell antibodies.

Authors:  S Sriram; D J Topham; S K Huang; M Rodriguez
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

9.  Susceptibility to Coxsackievirus B3-induced chronic myocarditis maps near the murine Tcr alpha and Myhc alpha loci on chromosome 14.

Authors:  M D Traystman; L H Chow; B M McManus; A Herskowitz; M N Nesbitt; K W Beisel
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

10.  Direct gene transfer with IP-10 mutant ameliorates mouse CVB3-induced myocarditis by blunting Th1 immune responses.

Authors:  Yan Yue; Jun Gui; Wenqing Ai; Wei Xu; Sidong Xiong
Journal:  PLoS One       Date:  2011-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.